Contract development and manufacturing organization Cambrex is celebrating its 40th anniversary, but that doesn’t mean it’s ready to rest on its laurels.
According to the East Rutherford-based company, Cambrex currently has more than $100 million in investments at work across its global manufacturing network. The largest – a $50 million project in Charles City, Iowa – will bolster the large-scale development and manufacturing of small molecule drug substances. Expected to come online in the first half of 2022, facility capacity will increase by about 30% with reactors up to 16,000 liters, which will allow for the efficient production of large-volume commercial drug substances, the company said.
In North Carolina, a High Point facility focused on clinical-stage drug substance and small-volume commercial manufacturing services is in the midst of a $30 million expansion that began last October. At its conclusion, expected for the first half of 2023 according to the company, the site will approximately double its capacity with the addition of new chemistry laboratories, clinical manufacturing suites and a small-scale commercial manufacturing operations with reactors up to 2,000 liters.
Across the Atlantic Ocean, Cambrex is halfway through a series of updates at its facility in Karlskoga, Sweden, that will total more than $20 million. The work will increase multi-purpose capacity by 25% while creating more flexibility in API manufacturing. Less than a year ago, a 6,000 liter drug substance production line was added in Karlskoga. Now, Cambrex said, a similar project is underway that will add more cGMP manufacturing capacity by the end of the year.
“As Cambrex celebrates our 40th anniversary, we are proud to be making significant investments in capacity and new capabilities across our network,” said Chief Executive Officer Thomas Loewald. “Paired with our growing team of over 2,200 employees; these investments will enable us to serve our customers better as we partner with them in the development and manufacturing of novel, life-changing therapies.”
1 of 1 article
0 articles remaining
Advance your business edge with news from NJBiz. Register now for more article access.